The present invention relates in essence to use of a compound, which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by a therapy which comprises re-directing of T-cells against target cells in a patient. Such a therapy includes, but is not limited to, treatment with an antibody comprising a CD3 binding domain, such as a CD20×CD3 or a CD19×CD3 bispecific single chain antibody, e.g., blinatumomab (MT-103). Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated, as are methods of identifying a compound for administration in the methods of prophylaxis, amelioration and/or treatment. Such anti-adhesive type compounds include, but are not limited to, antibodies, like natalizumab, efalizumab, and etrolizumab； minocycline, (acetyl-)salicyclic acid, astilbin, and flavonoids； and thrombin and pentosanpolysulfate (PPS), or a pharmaceutically acceptable salt thereof.La présente invention concerne en essence un composé qui diminue ou inhibe la liaison de lymphocytes T de mammifère à des cellules endothéliales de mammifère pour l'utilisation dans une méthode de prophylaxie et/ou d'amélioration et/ou de traitement d'événements indésirables cliniques provoqués par une thérapie qui comprend la redirection de lymphocytes T contre des cellules cibles chez un patient. L'invention concerne des méthodes de traitement de patients ayant ou présentant un risque d'avoir des événements indésirables cliniques provoqués par la thérapie qui comprend la redirection des lymphocytes T contre des cellules cibles.
